Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + Osimertinib +/- Ramucirumab in EGFR-Mutant, MET-Amplified Advanced NSCLC (Lung-MAP Sub-Study S1900G)
NCT05642572Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2023
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Arm A (capmatinib, osimertinib, ramucirumab) with Arm B (capmatinib, osimertinib) (2 arms). Primary endpoint: Investigator-assessed progression-free survival up to 3 years. Started May 2023; status: recruiting.
02
Drugs
capmatinibramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05642572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642572.